A Phase 1/2, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BBT-176 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Agent
Latest Information Update: 12 Jun 2025
At a glance
- Drugs BBT 176 (Primary) ; Cetuximab
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Bridge Biotherapeutics
Most Recent Events
- 29 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 30 Oct 2023 According to a Bridge Biotherapeutics media release,in September 2023,company announced the discontinuation of the development of BBT-176, at the Phase 1a stage, dose escalation part.
- 16 Oct 2023 Status changed from recruiting to active, no longer recruiting.